HC Wainwright Reiterates Buy Rating for GH Research (NASDAQ:GHRS)

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 316.23% from the stock’s previous close.

A number of other analysts also recently issued reports on GHRS. Canaccord Genuity Group dropped their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday. JMP Securities reissued a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Price Performance

Shares of GHRS stock opened at $9.61 on Wednesday. GH Research has a 1-year low of $5.05 and a 1-year high of $14.99. The firm’s 50-day simple moving average is $7.82 and its 200-day simple moving average is $10.33. The firm has a market cap of $499.99 million, a P/E ratio of -12.16 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. Analysts expect that GH Research will post -0.85 earnings per share for the current fiscal year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its position in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).